City
Epaper

Study shows how gut microbiome raises risk of multiple sclerosis

By IANS | Updated: February 21, 2025 10:50 IST

New Delhi, Feb 21 Gut microbiome plays a significant role in the onset of multiple sclerosis (MS) -- ...

Open in App

New Delhi, Feb 21 Gut microbiome plays a significant role in the onset of multiple sclerosis (MS) -- an autoimmune disease that impacts the central nervous system, finds a study that may provide answers to why some people develop the condition.

The microbiome in the gut comprises trillions of bacteria and other microorganisms that live in our digestive tracts, and are connected to human health and disease.

Researchers from Yale University in the US identified gut bacteria that had significantly different levels of abundance in patients with MS. Compared to healthy individuals, MS patients also had a smaller number of bacteria coated in an antibody known as host immunoglobulin A (IgA).

"The fact that fewer bacteria were coated with IgA in patients with MS suggests that there is perhaps a fundamental disconnect going on with the host-microbe interactions," said Erin Longbrake, Associate Professor of neurology and the study's principal investigator. Longbrake said that "theoretically, environmental risk factors could predispose people to MS because they change the bugs that are in the gut."

For the study, published in the Neurology Neuroimmunology and Neuroinflammation, the team included 43 people who were newly diagnosed with MS and had not started any sort of immune therapy to treat the disorder. These were compared with 42 healthy controls.

Analysis of their stool samples showed that species of Faecalibacterium were less abundant in patients with MS, while species of Monoglobus was more abundant in untreated MS patients.

Of the 43 people with MS, 19 gave the researchers an additional stool sample six months after starting B-cell depletion therapy -- a treatment that destroys immune cells that contribute to autoimmune diseases.

The gut microbiomes of these patients more closely resembled the microbiomes of healthy controls than they had pre-treatment, the researchers found.

"This gives us some clues into the mechanisms underlying how this type of drug works to treat MS," Longbrake said. The findings might help explain why some people develop MS, but not others.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

NationalSwitch off lights on April 30 for 15 min: AIMPLB calls for fresh stir against Waqf Act

NationalRLM Chief Upendra Kushwaha bats for census and delimitation

NationalMaharashtra govt reclaims sword of Maratha leader Raghuji Bhonsle

NationalWhat PM Modi's free hand to armed forces against terror means for cross-border action?

Other SportsKalinga Super Cup: Mumbai City, Jamshedpur eye first trip to final

Health Realted Stories

HealthStar Health's profit crashes 99.76 pc in Q4

HealthAyush Ministry to hold national conclave to boost traditional healthcare delivery

HealthWorld Immunisation Week: Vaccines saved 38 million lives SE Asia, says WHO

HealthGujarat: Jan Aushadhi Kendra becomes a boon for Jamnagar people, offering medicines at low price

HealthWhy treating depression in teenagers may be easier than in adults